CX Institutional Lowers Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

CX Institutional lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,232 shares of the medical research company’s stock after selling 112 shares during the quarter. CX Institutional’s holdings in Charles River Laboratories International were worth $597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Wolff Wiese Magana LLC bought a new stake in Charles River Laboratories International in the 3rd quarter worth about $32,000. Versant Capital Management Inc increased its holdings in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares in the last quarter. Assetmark Inc. increased its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the 3rd quarter worth about $59,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on CRL. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday. Bank of America reduced their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. UBS Group restated a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. TD Cowen boosted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, Citigroup downgraded Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price target for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $204.38.

Insider Buying and Selling

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Down 1.2 %

NYSE CRL opened at $164.88 on Friday. The stock’s 50 day moving average is $186.75 and its 200 day moving average is $197.21. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12 month low of $160.85 and a 12 month high of $275.00. The stock has a market cap of $8.43 billion, a PE ratio of 20.64, a P/E/G ratio of 5.94 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the previous year, the firm earned $2.72 EPS. The firm’s revenue was down 1.6% compared to the same quarter last year. Research analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).